GLP-1 Weight Loss Calculator
Wondering what weight loss with a GLP-1 medication could look like over time?
Use the GLPIANS GLP-1 Weight Loss Calculator to explore research-based weight-loss scenarios for semaglutide and tirzepatide, visualize how body weight may change over time, and understand why maintaining lean mass deserves attention during significant weight loss.
Important: This calculator is an educational modeling tool, not a prediction of your personal results. Clinical-trial averages describe groups of participants—not what will necessarily happen to an individual.
Start Your GLP-1 Weight-Loss Scenario
Enter your available starting information and select the medication scenario you want to explore.
Depending on the calculator's final validated methodology, the experience can help you explore:
weight-loss scenarios over time;
semaglutide and tirzepatide research benchmarks;
the difference between starting weight and goal weight;
lean-mass considerations during weight reduction;
protein and nutrition considerations;
questions worth discussing with your healthcare professional before treatment.
The purpose isn't to tell you exactly what you'll weigh 52 weeks from now.
It's to give you a clearer way to understand the evidence before you start.
Quick Answer: How Much Weight Can People Lose on GLP-1 Medications?
There is no single percentage that applies to everyone.
In STEP 1, adults with overweight or obesity without diabetes who received once-weekly semaglutide 2.4 mg plus lifestyle intervention lost an average of 14.9% of their starting body weight after 68 weeks, compared with 2.4% in the placebo group. (New England Journal of Medicine)
Tirzepatide has also produced substantial average weight reductions in randomized obesity trials. The FDA's original Zepbound approval summary reported that adults without diabetes receiving the highest approved dose in the pivotal study lost about 18% of their starting body weight on average after 72 weeks under the FDA's reported efficacy analysis. (U.S. Food and Drug Administration)
Those numbers are useful benchmarks.
They are not personal forecasts.
Your results can differ because clinical trials describe averages across populations, while individual outcomes vary.
That's the distinction this calculator is designed to keep visible.
What Is a GLP-1 Weight Loss Calculator?
A GLP-1 weight loss calculator is an educational tool that translates published weight-loss evidence into a more understandable visual scenario.
Instead of reading:
“Average body-weight change was X% at week Y”
you can explore what a similar percentage would mathematically represent from a given starting weight.
For example, a calculator can convert a research benchmark into pounds and display it visually over time.
But there is an important limitation:
Mathematical conversion is not medical prediction.
If a trial population averaged a certain percentage of weight reduction, multiplying your current weight by that percentage doesn't mean you personally will lose that amount.
GLPIANS therefore treats calculator outputs as research-informed scenarios, not promises.
Semaglutide Weight-Loss Calculator: What Does the Evidence Show?
Semaglutide is the active ingredient in both Wegovy and Ozempic, but those brand names should not be treated as interchangeable.
Wegovy has FDA-approved indications that include long-term reduction of excess body weight in eligible patients, while Ozempic has different approved indications. Current Wegovy prescribing information identifies semaglutide as a GLP-1 receptor agonist. (FDA Access Data)
For obesity treatment, one of the foundational studies is STEP 1.
The randomized trial included 1,961 adults with overweight or obesity who did not have diabetes. Participants received lifestyle intervention plus either semaglutide 2.4 mg or placebo for 68 weeks.
Average body-weight change was:
| STEP 1 group | Mean weight change at Week 68 |
|---|---|
| Semaglutide 2.4 mg | −14.9% |
| Placebo | −2.4% |
(New England Journal of Medicine)
This makes STEP 1 useful for understanding what happened in a defined research population.
It does not establish a personalized semaglutide weight-loss equation.
Using an Ozempic Weight Loss Calculator
People frequently search for an “Ozempic weight loss calculator,” but medication context matters.
Semaglutide is the active ingredient in both Ozempic and Wegovy, yet brand, indication, dose, population and trial context can differ.
A responsible calculator should therefore avoid assuming that results from a Wegovy obesity trial automatically predict results for every person taking any semaglutide product.
Using a Wegovy Weight Loss Calculator
For someone researching Wegovy specifically, STEP trial evidence provides useful population-level context.
The appropriate interpretation is:
“Here is what happened on average in this studied population.”
Not:
“Here is exactly how much weight you will lose.”
That difference matters.
Zepbound Weight Loss Calculator: What About Tirzepatide?
Tirzepatide works differently from semaglutide.
The FDA describes Zepbound as activating receptors for both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Zepbound is the tirzepatide brand approved for chronic weight management in eligible patients; tirzepatide is also marketed as Mounjaro for a different approved use. (U.S. Food and Drug Administration)
In the pivotal obesity trial discussed in the FDA's Zepbound approval, adults without diabetes receiving the highest approved dosage lost approximately 18% of starting body weight on average after 72 weeks under the reported analysis. (U.S. Food and Drug Administration)
Again, this is a population average.
It doesn't mean entering “Zepbound” and your starting weight into a calculator can scientifically determine your weight 72 weeks later.
Semaglutide vs. Tirzepatide Calculator
It can be useful to place research benchmarks next to one another, but comparisons require care.
Different trials can involve different:
populations;
treatment durations;
study designs;
doses;
discontinuation patterns;
statistical approaches;
lifestyle interventions.
For that reason, simply placing percentages from separate studies beside one another should not be interpreted as a head-to-head determination of which medication is right for you.
Medication choice is a clinical decision to discuss with an appropriate healthcare professional.
Why Your Actual Weight Loss May Look Different
Clinical averages flatten enormous amounts of individual variation into one number.
Your real trajectory doesn't have to follow a smooth calculator curve.
That is one reason GLPIANS intentionally separates a scenario from a prediction.
A calculator can show:
Starting weight → research benchmark → mathematical scenario
It cannot reliably establish:
Your body → your exact response → your exact future weight
The latter would require a validated individualized prediction model, not simply published population averages.
This is particularly important when looking at weekly graphs.
A smooth line may be useful for visualization, but it should not imply that human weight loss occurs according to an exact mathematical curve.
Weight Loss Isn't Necessarily All Body Fat
The scale tells you how much total body weight changed.
It doesn't tell you what changed.
Weight reduction can involve changes in both fat mass and lean mass.
A DXA substudy of SURMOUNT-1 examined body composition in 160 participants with overweight or obesity. At Week 72, participants receiving pooled tirzepatide doses had reductions in body weight, fat mass and lean mass. Approximately 75% of the weight lost was fat mass and approximately 25% was lean mass in this substudy. (PubMed)
That doesn't mean every person taking tirzepatide will lose exactly 25% of their weight from lean tissue.
It demonstrates something more useful:
Total pounds lost and body composition are not the same outcome.
That is why a GLP-1 journey shouldn't be evaluated only by the number on the scale.
GLP-1 Protein Calculator: Why Protein Deserves Attention
Reduced appetite can make adequate nutrition harder for some people using GLP-1 medications.
A 2025 multidisciplinary advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society specifically addresses nutritional priorities during GLP-1 therapy. It emphasizes adequate dietary protein and the importance of resistance/strength training for supporting muscle preservation. (PubMed)
But there is no justification for telling every GLP-1 user:
“Your exact protein requirement is body weight × 1.8 g/kg.”
Protein needs can depend on factors including body composition, age, activity, overall energy intake, health status and other clinical considerations.
The multidisciplinary advisory also makes an important point: increased protein alone is unlikely to be sufficient for supporting muscle preservation without structured resistance/strength training. (PubMed Central (PMC))
What the GLPIANS Protein Module Should Do
Instead of presenting one number as a medical prescription, the calculator should provide an educational planning range or reference point, clearly explaining the assumptions behind it.
People who need individualized nutrition targets—particularly those with relevant medical conditions—should discuss them with a qualified healthcare professional or registered dietitian.
What About a GLP-1 Macro Calculator?
Calories, protein, carbohydrates and fats don't become irrelevant simply because someone is considering GLP-1 treatment.
But a GLP-1 macro calculator should not pretend that medication use creates one universally correct macronutrient ratio.
For someone preparing for treatment, a better question is:
“Will my reduced appetite still allow me to get enough nutrition?”
That shifts the focus from chasing a perfect macro percentage to understanding nutritional adequacy.
The 2025 multidisciplinary advisory notes that reduced appetite and food aversions can make adequate protein intake challenging for some GLP-1 users and discusses nutrient-dense protein options and broader nutritional assessment. (PubMed Central (PMC))
That is a much stronger foundation for GLPIANS than an arbitrary “perfect GLP-1 macros” formula.
What About Side Effects?
Gastrointestinal adverse effects are well established with these medications.
The FDA's Zepbound approval information lists adverse effects including nausea, diarrhea, vomiting, constipation and abdominal discomfort, among others. (U.S. Food and Drug Administration)
Current Wegovy prescribing information likewise contains detailed adverse-reaction, warning and precaution information. (FDA Access Data)
However, knowing population-level adverse-event rates does not automatically allow a calculator to determine:
“Your nausea risk is 37%.”
A personal risk score requires a validated model demonstrating that the variables collected by the calculator can actually predict that outcome.
Until GLPIANS has such validation, a safer module would display:
clinical-trial/reference information + known factors/limitations + questions for your clinician
rather than a personalized probability.
Before Starting a GLP-1: Five Better Questions to Ask
A calculator is most valuable when it improves the conversation that happens next.
Consider discussing questions such as these with your healthcare professional:
Is this medication appropriate for my health history and treatment goals?
What results are realistic for someone with my clinical circumstances?
Which adverse effects and warning signs should I understand before starting?
How should I approach nutrition and maintaining muscle during weight loss?
How will we evaluate whether treatment is working appropriately for me?
Those answers are more clinically meaningful than trying to make a calculator generate false precision.
What This Calculator Can — and Cannot — Tell You
| The calculator can help you… | It cannot tell you… |
|---|---|
| Understand published trial averages | Exactly how much weight you will lose |
| Visualize mathematical weight-loss scenarios | Your exact weight at Week 52 |
| Compare research contexts | Which prescription you should take |
| Understand lean-mass considerations | Exactly how much muscle you will lose |
| Explore nutrition considerations | Your medically required protein intake |
| Prepare better questions | Whether a medication is safe for you personally |
| Understand uncertainty | Replace your clinician |
That limitation isn't a weakness.
It is what makes the tool more trustworthy.
Why GLPIANS Built This Calculator
Most people researching GLP-1 treatment don't begin with a clinical-trial paper.
They begin with questions.
How much weight might people lose?
How long does it take?
What happens to muscle?
How should nutrition change?
What should I know before starting?
GLPIANS built this educational calculator to bring those questions into one interactive pre-starter experience.
No calculator can show your future.
But good evidence can help you ask better questions about it.
Use the GLP-1 Weight Loss Calculator
Enter your information above to explore the calculator.
Change the available inputs and compare scenarios—but remember what you're looking at:
an educational model informed by published evidence, not a guarantee of your personal outcome.
If you're considering semaglutide, tirzepatide or another prescription treatment, use the results as a starting point for an informed discussion with your healthcare professional.
Want to prepare beyond the number on the scale?
The GLPIANS GLP-1 Success Audit walks through seven commonly overlooked areas that can make the GLP-1 journey more complicated.
FAQ
Is a GLP-1 weight loss calculator accurate?
A GLP-1 calculator can accurately perform the mathematics built into its methodology, but that is different from accurately predicting an individual's future weight. Published trials provide population averages, and individual outcomes vary. A calculator should therefore be interpreted as an educational scenario tool unless its personalized prediction model has been independently validated.
How much weight can you lose on semaglutide?
In STEP 1, adults with overweight or obesity without diabetes who received semaglutide 2.4 mg plus lifestyle intervention lost an average of 14.9% of starting body weight at 68 weeks, versus 2.4% with placebo. Individual outcomes vary. (New England Journal of Medicine)
How much weight can you lose on Zepbound?
The FDA reported that adults without diabetes receiving the highest approved Zepbound dose in the larger pivotal weight-management trial lost about 18% of starting body weight on average after 72 weeks under the reported analysis. This is a trial average, not an individual prediction. (U.S. Food and Drug Administration)
Is Ozempic the same as Wegovy?
Both contain semaglutide, but they should not be treated as identical products because their FDA-approved indications and prescribing contexts differ. Current Wegovy labeling should be consulted for Wegovy-specific information. (FDA Access Data)
Is Mounjaro the same as Zepbound?
Both contain tirzepatide, but they have distinct FDA-approved uses. The FDA approved Zepbound for chronic weight management in eligible adults in 2023, while Mounjaro had already been approved for improving glycemic control in adults with type 2 diabetes. (U.S. Food and Drug Administration)
Do GLP-1 medications cause muscle loss?
Weight reduction can include both fat mass and lean mass. In a SURMOUNT-1 DXA substudy, approximately 25% of weight lost among participants receiving tirzepatide represented lean mass on average, but this should not be interpreted as a universal individual percentage. (PubMed)
How much protein should I eat on a GLP-1?
There isn't one automatically correct protein number for every GLP-1 user. Current professional guidance emphasizes adequate protein alongside resistance training, while individual needs can vary. Personalized targets may warrant assessment by a qualified healthcare professional or registered dietitian. (PubMed)
Can this calculator tell me whether I should take Wegovy or Zepbound?
No. Medication selection depends on individual clinical circumstances and belongs in a discussion with an appropriate healthcare professional. The calculator is designed for education and scenario exploration, not prescribing.
REFERENCES / SOURCES
Wilding JP et al. — STEP 1, New England Journal of Medicine (2021). Randomized trial of once-weekly semaglutide 2.4 mg in adults with overweight or obesity without diabetes. (New England Journal of Medicine)
Read STEP 1 at NEJM
U.S. Food and Drug Administration — Zepbound approval (2023). FDA approval summary covering indication, pivotal weight-management evidence and major safety information. (U.S. Food and Drug Administration)
FDA Zepbound approval information
U.S. Food and Drug Administration — Wegovy Prescribing Information (2026). Current FDA labeling for semaglutide/Wegovy. (FDA Access Data)
Current FDA Wegovy Prescribing Information
Look M et al. — SURMOUNT-1 body-composition substudy (2025). DXA analysis examining changes in fat and lean mass with tirzepatide. (PubMed)
SURMOUNT-1 body-composition study on PubMed
Mozaffarian D et al. — Nutritional Priorities to Support GLP-1 Therapy for Obesity (2025). Joint advisory from four professional organizations addressing nutrition, protein, muscle preservation and other lifestyle considerations. (PubMed)
GLP-1 nutrition joint advisory on PubMed
